Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Allergen Challenge Trial of 6 Repeat Doses of IRL201104 in Adult Participants With Seasonal Allergic Rhinitis

Next Previous
X
Search
Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Allergen Challenge Trial of 6 Repeat Doses of IRL201104 in Adult Participants With Seasonal Allergic Rhinitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IRL 201104 (Primary)
  • Indications Allergic rhinitis; Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Revolo Biotherapeutics

    • Most Recent Events

    • 25 Oct 2023 Results published in the Media Release
    • 27 Mar 2023 Status changed to completed, according to a Revolo Biotherapeutics media release
    • 27 Mar 2023 According to a Revolo Biotherapeutics media release, company today announced that last patient has completed twelve-week this trial. The company anticipates top-line data and data readout for the EoE data from the study during the second quarter of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top